Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Psychiatry/Cocaine Use Disorder

Cocaine Use Disorder

10

Pipeline Programs↗

14

Active Trials↗

7

Companies Involved↗

Cocaine Use Disorder is an early-stage landscape with 10 programs across 7 companies.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

30/100

Mech. Concentration

33/100

Completion Rate

71/100

Attrition Rate

10/100

Pipeline

Programs by Phase

Preclinical3

Buspirone

Bristol-Myers Squibb

4-Aminopyridine (4-AP)

Boris Quednow

Cobenfy

Joshua A. Lile, Ph.D.

Phase 13

[f-18]bcpp-Ef

Rajesh Narendran

Psilocybin

COMPASS Pathways

AAV8-Hcoch

W. Michael Hooten

Phase 24

Semaglutide

Novo Nordisk

D-Amphetamine

Noven Pharmaceuticals, Inc.

Clavulanic Acid

Temple University

Dexamphetamine

The Netherlands Cancer Institute

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

71%

Small molecule

5 of 7 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 70% of 10 pipeline programs.

Analysis

Trial Status

29

clinical trials

Recruiting10 · 34%

Completed10 · 34%

Active, not recruiting3 · 10%

Terminated2 · 7%

Unknown status1 · 3%

Suspended1 · 3%

Other2 · 7%

Clinical Trials

Trial Activity

29 trials

Open-label Feasibility Trial of HD-tDCS During Cognitive Behavioral Therapy for Cocaine Use Disorder

Recruiting·VVirginia Commonwealth University·Preclinical·NCT07829263·36 enrolled

Imaging Brain Energy Use in Cocaine Use Disorder: a [F-18]BCPP-EF PET Study

Recruiting·—·Phase 1·NCT07773649·40 enrolled

The Impact of Cobenfy Maintenance on Cocaine's Effects

Recruiting·JJoshua A. Lile, Ph.D.·Preclinical·NCT07624227·32 enrolled

Randomised, Double-Blind, Placebo-Controlled, Crossover Study Investigating the Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users

Recruiting·—·Preclinical·NCT07532460·40 enrolled

Imaging Corticotrophin-releasing Factor (CRF) X Nociceptive Opioid Peptide (NOP) Interactions in Cocaine Use Disorders (Aim 1)

Recruiting·—·Phase 1·NCT05008146·80 enrolled

[C-11]NPA PET-amphetamine in Cocaine Use Disorders (Aim 2)

Recruiting·—·Phase 1·NCT05011760·30 enrolled

Contingency Management Plus Deep Transcranial Magnetic Stimulation for the Treatment

Recruiting·TThe University of Texas Health Science Center, Houston·Preclinical·NCT07490600·100 enrolled

Safety Profile of Psilocybin for Cocaine Use Disorder

Recruiting·UUniversity of California, Los Angeles·Phase 1·NCT06102434·10 enrolled

AAV8-hCocH for Cocaine Use Disorder

Recruiting·—·Phase 1·NCT04884594·10 enrolled

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

Recruiting·TThe University of Texas Health Science Center, Houston·Phase 2·NCT07227948·75 enrolled

Evaluation Of Semaglutide Safety and Tolerability in Adults With Cocaine Use Disorder With and Without HIV

Active, not recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT06691243·40 enrolled

Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study

Active, not recruiting·YYale University·N/A·NCT04721418·80 enrolled

Clavulanic Acid for the Treatment of Cocaine Use Disorder

Active, not recruiting·TTemple University·Phase 2·NCT05562349·65 enrolled

Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder

Not yet recruiting·PParnassia Addiction Research Centre·Phase 2·NCT05529927·204 enrolled

Exenatide for Treating Cocaine Use Disorder

Completed·TThe University of Texas Health Science Center, Houston·Phase 1/2·NCT04941521·3 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)